Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I
NCT03053089
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Mucopolysaccharidosis I
Interventions
DRUG:
AGT-181
Sponsor
ArmaGen, Inc